Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and safety monitoring of etanercept versus ustekinumab in psoriasis with joint involvement
2017-001695-26Phase 4Completed
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept and ustekinumab in psoriasis and psoriatic arthritis (PsA) (2 arms), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Minimal Disease Activity at week 12. Started Nov 2020; status: completed.
02
Drugs
etanerceptustekinumab
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2017-001695-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001695-26.